<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30057641</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>01</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">1735-1995</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>23</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences</Title>                <ISOAbbreviation>J Res Med Sci</ISOAbbreviation>            </Journal>            <ArticleTitle>The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine.</ArticleTitle>            <Pagination>                <MedlinePgn>57</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.4103/jrms.JRMS_644_17</ELocationID>            <Abstract>                <AbstractText Label="Background" NlmCategory="UNASSIGNED">A decision analysis model was developed to assess the cost-effectiveness of adriamycin and cyclophosphamide (AC) in comparison with paclitaxel and gemcitabine (PG) in women with advanced breast cancer in Iran.</AbstractText>                <AbstractText Label="Materials and Methods" NlmCategory="UNASSIGNED">This is a cost-effectiveness analysis performed as a cross-sectional study in Namazi Hospital in Shiraz, Iran. Patients were divided into two groups by random numbers, 32 women in the AC group and 32 women in the PG group. The costs were measured using the societal perspective and effectiveness of 2 regimens were assessed using tumor response. By a decision tree, the incremental cost-effectiveness ratio was calculated. In addition, the robustness of results was examined by sensitivity analysis.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">The estimated total cost of AC and PG per patient was 1565.23 ± 765.31 and 2099.08 ± 926.99, respectively. Response to treatment in AC and PG arm were 84% versus 75% respectively. The incremental cost-effectiveness ratio results showed AC is a dominate alternative.</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Overall, AC was a simple dominate strategy. In other words, AC was estimated to have a lower cost and greater effectiveness than PG.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Javan-Noughabi</LastName>                    <ForeName>Javad</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rezapour</LastName>                    <ForeName>Aziz</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kassani</LastName>                    <ForeName>Aziz</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Community Medicine, Dezful University of Medical Sciences, Dezful, Iran.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hatam</LastName>                    <ForeName>Nahid</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Health Administration, School of Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ahmadloo</LastName>                    <ForeName>Niloofar</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>06</Month>                <Day>06</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>India</Country>            <MedlineTA>J Res Med Sci</MedlineTA>            <NlmUniqueID>101235599</NlmUniqueID>            <ISSNLinking>1735-1995</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2004 Feb;15(2):201-6</RefSource>                <PMID Version="1">14760109</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2004 Sep;5(9):568-74</RefSource>                <PMID Version="1">15337487</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Health Econ. 2011 Aug;12(4):311-7</RefSource>                <PMID Version="1">20306109</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2016 Oct;66:162-70</RefSource>                <PMID Version="1">27589247</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2005 Oct 1;23(28):7098-104</RefSource>                <PMID Version="1">16192593</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2003 Mar 15;21(6):976-83</RefSource>                <PMID Version="1">12637460</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA Oncol. 2015 Jul;1(4):505-27</RefSource>                <PMID Version="1">26181261</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Oncol. 2011 Dec;18(6):e288-96</RefSource>                <PMID Version="1">22184496</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Acta Oncol. 2008;47(6):1113-21</RefSource>                <PMID Version="1">18607866</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2008 Jul-Aug;58(4):231-44</RefSource>                <PMID Version="1">18596196</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cancer Res Ther. 2005 Jan-Mar;1(1):21-30</RefSource>                <PMID Version="1">17998621</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Oncol. 2011 Apr;18(2):67-75</RefSource>                <PMID Version="1">21505597</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pharmacoeconomics. 2009;27(10):873-86</RefSource>                <PMID Version="1">19803541</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2013 Nov;14(12):1165-74</RefSource>                <PMID Version="1">24131614</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2009 Jul;45(11):1987-91</RefSource>                <PMID Version="1">19398326</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2010 Feb 24;102(4):230-43</RefSource>                <PMID Version="1">20118413</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2002 Jan;13(1):108-15</RefSource>                <PMID Version="1">11863090</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2009 Mar;20(3):556-63</RefSource>                <PMID Version="1">19073863</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Semin Oncol. 2004 Apr;31(2 Suppl 5):31-6</RefSource>                <PMID Version="1">15199530</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2010 Jan 20;102(2):82-8</RefSource>                <PMID Version="1">20056956</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2017 Feb 25;389(10071):847-860</RefSource>                <PMID Version="1">27814965</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Res Med Sci. 2013 Apr;18(4):283-90</RefSource>                <PMID Version="1">24124424</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Res Med Sci. 2015 Aug;20(8):751-6</RefSource>                <PMID Version="1">26664422</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90</RefSource>                <PMID Version="1">21296855</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Iran Med. 2010 Mar;13(2):143-6</RefSource>                <PMID Version="1">20187669</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer Care (Engl). 2007 Nov;16(6):500-7</RefSource>                <PMID Version="1">17944764</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast neoplasms</Keyword>            <Keyword MajorTopicYN="N">cost-benefit analysis</Keyword>            <Keyword MajorTopicYN="N">cyclophosphamide</Keyword>            <Keyword MajorTopicYN="N">doxorubicin</Keyword>            <Keyword MajorTopicYN="N">paclitaxel</Keyword>        </KeywordList>        <CoiStatement>There are no conflicts of interest.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>08</Month>                <Day>30</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>02</Month>                <Day>27</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>03</Month>                <Day>14</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>7</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30057641</ArticleId>            <ArticleId IdType="doi">10.4103/jrms.JRMS_644_17</ArticleId>            <ArticleId IdType="pii">JRMS-23-57</ArticleId>            <ArticleId IdType="pmc">PMC6040151</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>